Hong Kong Stock Movement: BIOSINO BIO-TEC fell 16.67%, with active trading attracting market attention

Hong Kong Stock Movement BIOSINO BIO-TEC fell 16.67%, with no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Stocks Ranked Among the Top in Industry Transaction Volume Innovent Biologics fell 4.99%. Based on recent key news: On November 20, Innovent Biologics announced that its MaShidu peptide achieved the primary endpoint in a Phase III clinical study in the Chinese obese population, showing significant weight loss effects. This news attracted market attention, leading to noticeable stock price fluctuations. Source: Zhitong Finance On November 21, the Hang Seng Index Company announced the results of its quarterly review, listing Innovent Biologics as one of the sectors worth watching, with the market full of expectations for its future performance. Source: Economic Information Daily On November 19, Zhongtai International released an overview of the Hong Kong pharmaceutical industry, pointing out that innovative drugs led the rebound of the Hang Seng Healthcare Index, with Innovent Biologics recommended as a key focus. Source: Jinwu Finance, the development of innovative drugs in the pharmaceutical industry is supported. 3SBio fell 8.09%. Based on recent key news: On November 20, 3SBio announced the spin-off of its Mandi shares for independent listing on the main board of the Stock Exchange. This move raised market concerns about the company's future development direction, leading to a decline in stock price. Zhitong Finance reported that the spin-off of Mandi shares will be conducted through a physical distribution method, involving a global offering. Mandi International has submitted a listing application to the Stock Exchange. On November 21, Economic Information Daily reported that 3SBio's stock price fell 7.2%, with a transaction volume of HKD 303 million. The news of the spin-off of Mandi International raised investor concerns about the company's strategic adjustments, affecting stock price performance. On November 20, Pfizer updated its SSGJ-707 clinical development plan, positioning it as a cornerstone therapy for cross-tumor immunotherapy. Although Pfizer's plan shows market potential, the news of 3SBio's spin-off still dominated market sentiment, leading to stock price fluctuations. The biopharmaceutical industry has seen significant volatility recently and requires attention. BeiGene fell 4.35%. Based on recent key news: On November 18, Founder Securities pointed out that the innovative drug market is adjusting, with some Hong Kong stocks experiencing severe fluctuations, leading to doubts about the logic of innovative drugs, which caused BeiGene's stock price to fall. Founder Securities believes that the core logic of innovative drugs remains unchanged, and BeiGene's third-quarter report stabilized market sentiment, highlighting the potential of Chinese original innovative drugs in the international market. On November 19, BeiGene's third-quarter performance exceeded expectations, with global revenue from Zebrutinib increasing by 51%, bringing the stock price back near previous highs. Despite the decline in the heat of the innovative drug market, BeiGene's performance stood out, becoming a market highlight. On November 21, the Hang Seng Index Company will announce the results of its quarterly review, with BeiGene listed as one of the potential candidates for inclusion in the Hang Seng Index. Analysts believe that its continuous profitability and positive yield performance make it a focus during the Hang Seng Index adjustment. The innovative drug market is adjusting, and capital flows are fluctuating Stocks Ranked Among the Top by Market Capitalization in the Industry Kangfang Biotech fell 3.45%. Based on recent news, On November 20th, the bispecific antibody AK152 developed by Kangfang Biotech demonstrated significant biological activity and good safety characteristics in preclinical studies. This drug is expected to bring new hope to Alzheimer's patients and show potential in the treatment of metabolic diseases. However, there remains uncertainty in the market regarding its future performance, leading to stock price fluctuations. On November 18th, UBS released a market strategy report for China, listing Kangfang Biotech among the "Buy" rated Chinese stocks with high profit growth potential for next year. Despite the positive rating, market reactions were mixed, and the stock price still experienced a decline. No other significant news recently. The bispecific antibody market has broad prospects, and competition in the industry is fierce